Jun 11, 2024 08:00AM
May 14, 2024 04:01PM
Mar 5, 2024 04:02PM
Dec 20, 2023 08:01AM
Dec 20, 2023 08:00AM
Nov 9, 2023 04:02PM
Sep 18, 2023 08:03AM TRACON Pharmaceutical (TCON) Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
Sep 18, 2023 08:00AM
Aug 14, 2023 04:02PM
Jul 11, 2023 08:04AM
Jul 11, 2023 08:00AM
Jun 20, 2023 08:03AM
Jun 20, 2023 08:00AM
May 30, 2023 08:00AM TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting
May 10, 2023 04:02PM
Apr 25, 2023 07:42AM
Apr 25, 2023 07:41AM
Mar 8, 2023 04:02PM
Dec 14, 2022 08:02AM
Dec 14, 2022 08:00AM
Nov 21, 2022 08:00AM TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma
Nov 14, 2022 04:02PM
Oct 6, 2022 08:04AM
Oct 6, 2022 08:00AM
Sep 14, 2022 08:00AM
Sep 14, 2022 08:00AM
Aug 30, 2022 05:59AM
Aug 29, 2022 08:00PM US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
Aug 29, 2022 08:00PM
Aug 29, 2022 08:02AM
Aug 29, 2022 08:00AM
Aug 10, 2022 04:02PM
Aug 8, 2022 08:02AM
Aug 8, 2022 08:00AM
Jul 26, 2022 08:05AM TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter
May 11, 2022 04:02PM
Apr 19, 2022 08:13AM
Apr 19, 2022 08:05AM
Mar 15, 2022 04:03PM
Mar 15, 2022 04:02PM
Mar 10, 2022 08:05AM
Mar 10, 2022 08:05AM TRACON Pharmaceuticals Announces FDA Approval of Amended ENVASARC Protocol
Feb 2, 2022 08:05AM
Dec 27, 2021 08:00AM
Nov 29, 2021 08:06AM
Nov 29, 2021 08:05AM
Nov 3, 2021 04:02PM
Oct 11, 2021 08:00AM
Aug 11, 2021 04:02PM TRACON Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Jul 20, 2021 08:05AM

322,090 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All